William H. Crampton was appointed Director of Aterian, Inc. As of November 6, 2026, Aterian, Inc. has reported 5 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 29, 2026 to October 5, 2026, naming 1 appointment (Form 8-K, September 29, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Aterian, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-10-05
- · In / out: In · Person: William H. Crampton · Role: Director · 8-K, 2026-09-29
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-08
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-20
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-04-29
Aterian, Inc. reported changes in 5 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-29 to 2026-10-05. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Aterian, Inc. files it.
Also on the record for Aterian, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 2, 2026 | Stake report, Schedule 13D, by Chang Woei Jiann | 10% of the class | 5%+ stakes | Source |
| October 2, 2026 | Stake report, Schedule 13D, by Michelle Chiam Sin Ling | 10% of the class | 5%+ stakes | Source |
| September 29, 2026 | Stake report, Schedule 13D/A, by Lazar David E. | 3.1% of the class | 5%+ stakes | Source |
| September 10, 2026 | Stake report, Schedule 13D, by Lazar David E. | 95.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Aterian, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Aterian, Inc. and the records around it.
Aterian, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Lazar David E. also filed stake reports on 8 other companies: HIGHWAY HOLDINGS LTD (Nov 2026), MAINZ BIOMED N.V. (Aug 2026), KALA BIO, Inc. (Jul 2026)
Watch Aterian, Inc.
Get an email when Aterian, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Aterian, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Aterian, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aterian, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-05 | Reported | not named in the filing | 8-K, 2026-10-05 | ||
| 2026-09-29 | In | Director | 8-K, 2026-09-29 | ||
| 2026-09-08 | Reported | not named in the filing | 8-K, 2026-09-08 | ||
| 2026-07-20 | Reported | not named in the filing | 8-K, 2026-07-20 | ||
| 2026-04-29 | Reported | not named in the filing | 8-K, 2026-04-29 |
Who leads Aterian, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: William H. Crampton, appointed (filed 2026-09-29).
New leaders reset buying decisions — get the Full Report on Aterian, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Aterian, Inc., with the record behind each one.
Find candidates like Director at Aterian, Inc.Every change, in the filing's words
Reported
On September 30, 2026, Mr. Rodriguez's employment terminated pursuant to the Transition Agreement.
- On October 2, 2026 (the "Effective Date"), the Company entered into a consulting agreement with Mr. Rodriguez (the "Consulting Agreement"), which was approved by the Board of Directors of the Company (the "Board") and the Committee, pursuant to which the Company engaged Mr. Rodriguez as an independent contractor to provide limited advisory services.
- Pursuant to the Consulting Agreement, Mr. Rodriguez will receive $250 per hour for services performed, subject to a limit of 12 hours per week and an aggregate fee cap of $77,000.
- Mr. Rodriguez is expected to provide consulting services from the Effective Date through November 20, 2026, and thereafter on a month-to-month basis until terminated by either party, but in any event no later than March 31, 2027.
Appointed: William H. Crampton, Director
On September 25, 2026, the Board appointed William H. Crampton to serve as a member of the Board.
- Resignation of Director On September 23, 2026, the Company received the resignation of Avraham Ben-Tzvi as a member of the Board and from all committees of the Board, effective September 25, 2026.
- The resignation of Mr. Ben-Tzvi is not based on any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.
- The Board determined that Mr. Crampton satisfies all applicable independence and eligibility requirements for service on the Audit Committee and Compensation Committee of the Board.
- Effective September 25, 2026, Mr. Crampton was appointed to serve as a member of the Audit Committee and Compensation Committee of the Board.
- William H. Crampton, age 63, has served as a CXO of Stealth Company, a company focused on low-carbon energy systems since February 2026, where he is responsible for business development.
- Since July 2024, he has also served as Vice President of Business Development of TO Viridi, a company focused on carbon sequestration and green hydrogen technologies.
- From July 2003 to June 2024, Mr. Crampton served as Co-Founder and Chief Executive Officer of TreasureBeam, where he led business development and consulting activities in the renewable energy sector.
Reported
While the Company is looking for a full-time Chief Financial Officer to fill the vacancy created by Mr. Feldman's termination, the Company's Chief Executive Officer, David E. Lazar will serve as the interim Chief Financial Officer and principal financial officer of the Company.
- On September 4, 2026, Mr. Feldman, pursuant to such agreement, was terminated as Chief Financial Officer and principal financial officer, and Mr. Feldman was entitled to receive his severance benefits.
Reported
Change in Chief Executive Officer and Transition Services As previously announced, pursuant to the terms of the Securities Purchase Agreement, the Board agreed to appoint Lazar as the sole Chief Executive Officer of the Company promptly following the Second SPA Closing.
- Accordingly, on July 17, 2026, Lazar was appointed as the Chief Executive Officer of the Company.
- In connection with Lazar's appointment, Arturo Rodriguez's position as the Company's Chief Executive Officer terminated.
- However, on July 16, 2026, Mr. Rodriguez and the Company entered into a Transition and Separation Agreement (the "Rodriguez Agreement"), pursuant to which Mr. Rodriguez agreed to provide services to the Company as a non-executive employee to help ensure a smooth transition.
- Pursuant to the Rodriguez Agreement, Mr. Rodriguez will remain with the Company through September 30, 2026, at which time his employment with the Company will terminate and such termination of employment will be treated as a "Change in Control Qualifying Termination," as such term is defined in the Company's Executive Severance Plan (the "Severance Plan"), and he will be entitled to receive the severance benefits described in Section IV.02 thereof.
- Mr. Rodriguez will remain as a member of the Board and will serve as a member of the Special Committee of the Board (the "Special Committee") responsible for overseeing the Dividend.
Reported
Appointment of Director In connection with the transactions contemplated by, and immediately prior to the execution of, the Securities Purchase Agreement, the Board increased the authorized number of directors to five and appointed Lazar to the Board to fill the vacancy created by such increase, effective immediately, as a Class II director with a term expiring at the Company's 2027 annual meeting of stockholders.
- Pursuant to the Securities Purchase Agreement, subject to obtaining stockholder approval at the special meeting of the Company's stockholders, Lazar will have the right to recommend to the Company up to four individuals to be nominated for election at such meeting, provided that such right shall at all times be subject to, and in compliance with, Nasdaq Listing Rule 5640.
- Post-Closing Appointment of Chief Executive Officer In accordance with the Securities Purchase Agreement, the Board agreed to appoint Lazar as the sole Chief Executive Officer of the Company promptly following the Second SPA Closing.
- Mr. Rodriguez is expected to remain with Aterian to ensure a smooth transition of responsibilities.
- David E. Lazar (35) David Lazar currently serves as the CEO of Quantum Cyber N.V. (Formerly Mainz Biomed N.V.) (Nasdaq: QUCY) since February 2026, and Sow Good, Inc. (NASDAQ: SOWG) from January to March 2026.
- Lazar previously served as the CEO and Chairman of Indaptus Therapeutics, Inc. (Nasdaq: INDP) from December 2025 to April 2026 and is still serving on its board of directors.
- Previously Lazar served as the CEO and Chairman of Kala Bio Inc. (NASDAQ: KALA) from December 2025 to February 2026.
- Lazar previously served as CEO & Chairman of Novabay Pharmaceuticals, Inc. (NASDAQ: NBY) from August to November 2025.
Tools for this story
Each opens in a new tab, filled in for Aterian, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.